Medtronic reported fourth quarter revenue of $9.8 billion and non-GAAP EPS of $1.55, exceeding analyst expectations. For the full fiscal year 2026, the company posted revenue of $36.4 billion, an organic increase of 5.8%, and non-GAAP EPS of $5.53.

Key Highlights

  • Organic revenue grew 6.6% in the fourth quarter, surpassing the 6.0% consensus estimate and driven by broad-based strength.
  • The Cardiovascular portfolio was a primary growth driver, with revenue increasing 10.1% organically, led by a high-teens increase in Cardiac Rhythm & Heart Failure.
  • Notably, Cardiac Ablation Solutions revenue surged 78% globally, which included 124% growth in the U.S. market as the company gained market share.
  • Medtronic issued fiscal 2027 guidance for organic revenue growth of 6.75% to 7.25% and non-GAAP EPS between $5.90 and $6.00.